PTGS2 and Stroke: Similar to COX-2 genetic deletion, post-ischemic treatment with the highly selective COX-2 inhibitor, CAY10404, significantly reduced stroke size (Figure 5A), IgG extravasation (Figure 5B) and hemorrhagic transformation (Figure 5C) compared to the vehicle-treated group.